What is PAGE?

We represent a community with a shared interest in data analysis using the population approach.


2004
   Uppsala, Sweden

Modelling and simulation of the incidence of adverse events in clinical trials.

Filip De Ridder (1), An Vermeulen (2) and Vladimir Piotrovskij (2)

(1) Biometrics & Clinical Informatics; (2) Global Clinical Pharmacokinetics & Clinical Pharmacology, Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium.

PDF of presentation

Objectives: Predict the incidence of a pre-defined adverse event in dose ranging trials of a new compound. The adverse event of interest is typical for the class to which the new compound belongs.

Methods: A PK/PD model was developed using data from Phase II/III trials of a marketed compound of the same class (10 studies, ▒ 2500 patients). A time-to-event (hazard modelling) approach was used to model the incidence of the adverse event of interest (number of patients with at least 1 episode of the event/total number of patients randomised). This approach utilizes all available information and allows a flexible incorporation of time-varying covariates, including drug exposure, varying trial duration and dropout. A parametric model was developed describing the hazard as a function of time and covariates, including drug exposure. A similar model incorporating the drop out mechanism was also developed. Patient-specific measures of drug exposure were derived from an available population PK-model (developed in NONMEM). The hazard models were fitted by maximum likelihood and implemented in the SAS-procedure NLMIXED. The model was validated against other trials with the same compound. Using these hazard models, a population PK-model based on early Phase I data of the new compound, and adopting a few basic pharmacological and pharmacokinetic assumptions, clinical trial simulations were performed to predict the incidence of the adverse event in the planned dose-ranging trials. Sensitivity analyses were performed to assess to impact of uncertainty in some aspects of the model.

Results: The hazard for developing the adverse event of interest was best described by a steep - virtually on/off - relationship, with patient-specific average steady state concentration. This translated into shallow dose-response relationship for the new compound. Clinical trial simulation allowed to assess the incidence for the planned dose-ranging trials and to balance safety and efficacy.

Conclusion: Hazard modelling is a flexible tool to model the occurrence of (adverse) events in clinical trials. In this application, it allowed to synthesize relevant data of a marketed compound. Simulation allowed studying what can be expected in planned clinical trials based on available knowledge and gaps therein.



Top